PARP-1 inhibitor modulate β-catenin signaling to enhance cisplatin sensitivity in cancer cervix.
PARP-1
PJ34
cervical cancer
cisplatin
β-catenin
Journal
Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965
Informations de publication
Date de publication:
02 Jul 2019
02 Jul 2019
Historique:
received:
08
01
2019
accepted:
13
05
2019
entrez:
16
7
2019
pubmed:
16
7
2019
medline:
16
7
2019
Statut:
epublish
Résumé
Cisplatin is a keystone for treatment of both recurring and locally advanced cervical cancer. However toxic side effects and acquired resistance limits its efficacy. Enhanced DNA repair is one of the mechanisms through which cancer cells acquire cisplatin resistance. Inhibitors of PARP, which is a DNA damage repair enzyme, have been approved for use in BRCA mutated cancers like breast and ovary cancer. However little is known about the therapeutic efficacy of PARP inhibitors in cervical cancer, either as a single agent or in combination with cisplatin. We hypothesized that PARP-1 inhibition might improve the sensitivity of cervical cancer cells to cisplatin by diminishing DNA repair. To ascertain this, we determined effect of PARP-1 inhibition on cisplatin cytotoxicity in HeLa and SiHa cell lines. Combination of cisplatin with PJ34, a phenanthridinone-derived PARP-1 inhibitor, augmented cisplatin toxicity
Identifiants
pubmed: 31303961
doi: 10.18632/oncotarget.27008
pii: 27008
pmc: PMC6611509
doi:
Types de publication
Journal Article
Langues
eng
Pagination
4262-4275Commentaires et corrections
Type : ErratumIn
Déclaration de conflit d'intérêts
CONFLICTS OF INTEREST The authors declare no conflict of interest.
Références
Mutat Res. 2001 Jun 2;477(1-2):97-110
pubmed: 11376691
Nat Rev Cancer. 2002 Jun;2(6):442-54
pubmed: 12189386
Oncogene. 2003 Oct 20;22(47):7265-79
pubmed: 14576837
Cancer Chemother Pharmacol. 1992;29(6):430-4
pubmed: 1568285
Gastroenterology. 2005 Jun;128(7):1919-36
pubmed: 15940627
Mol Carcinog. 2005 Sep;44(1):51-9
pubmed: 16044419
Curr Opin Cell Biol. 2005 Oct;17(5):548-58
pubmed: 16098727
Pharmacol Rev. 2006 Sep;58(3):621-81
pubmed: 16968952
Cancer Res. 2007 Feb 1;67(3):911-8
pubmed: 17283121
Clin Cancer Res. 2007 Mar 1;13(5):1383-8
pubmed: 17332279
BMJ. 2007 Oct 13;335(7623):765-8
pubmed: 17932207
Oncol Rep. 2008 Sep;20(3):567-72
pubmed: 18695907
J Clin Oncol. 2009 Oct 1;27(28):4649-55
pubmed: 19720909
J Cell Physiol. 2010 Feb;222(2):401-10
pubmed: 19890834
Lancet. 2010 Jul 24;376(9737):235-44
pubmed: 20609467
Lancet. 2010 Jul 24;376(9737):245-51
pubmed: 20609468
Cancer Res. 2010 Oct 15;70(20):7970-80
pubmed: 20798217
BMC Cancer. 2010 Oct 13;10:553
pubmed: 20942921
Toxicol Mech Methods. 2011 Jan;21(1):6-12
pubmed: 21058936
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
pubmed: 21296855
Mol Oncol. 2011 Aug;5(4):387-93
pubmed: 21821475
DNA Repair (Amst). 2011 Oct 10;10(10):1003-13
pubmed: 21840268
Br J Cancer. 2011 Oct 11;105(8):1114-22
pubmed: 21989215
N Engl J Med. 2012 Apr 12;366(15):1382-92
pubmed: 22452356
Pharmacol Rev. 2012 Jul;64(3):706-21
pubmed: 22659329
Cell Cycle. 2013 Mar 15;12(6):877-83
pubmed: 23428903
Cancer Res. 2013 Apr 1;73(7):2271-80
pubmed: 23554447
FEBS Open Bio. 2012 Mar 05;2:26-31
pubmed: 23650577
Front Oncol. 2013 Dec 20;3:301
pubmed: 24392349
Expert Rev Clin Pharmacol. 2014 Mar;7(2):219-23
pubmed: 24490716
Lancet Oncol. 2014 Apr;15(5):489-538
pubmed: 24731404
BMC Womens Health. 2016 Jun 04;16:29
pubmed: 27259656
Onco Targets Ther. 2017 Feb 20;10:711-724
pubmed: 28260916
Science. 2017 Mar 17;355(6330):1152-1158
pubmed: 28302823
Oncol Lett. 2017 Apr;13(4):2847-2851
pubmed: 28454476
J Cancer. 2017 Jul 5;8(11):2114-2123
pubmed: 28819413
Sci Rep. 2017 Oct 9;7(1):12876
pubmed: 28993682
Gynecol Oncol. 2017 Dec;147(3):695-704
pubmed: 29037806
Oncotarget. 2018 Feb 5;9(17):13451-13461
pubmed: 29568369
Cancer Res. 2019 Jan 15;79(2):311-319
pubmed: 30482774
Cancer Res. 1988 Aug 15;48(16):4484-8
pubmed: 3395999
Proc Natl Acad Sci U S A. 1982 Jun;79(11):3423-7
pubmed: 6808510
Trends Biochem Sci. 1994 Apr;19(4):172-6
pubmed: 8016868
Br J Cancer. 1994 Jan;69(1):93-100
pubmed: 8286217
Cancer Lett. 1996 Nov 12;108(1):15-23
pubmed: 8950204